Immuneering (NASDAQ: IMRX) director receives 33,350 stock options grant

Rhea-AI Filing Summary

Immuneering Corp director Laurie Keating received a grant of 33,350 stock options. These options allow her to buy Class A common stock at an exercise price of $4.12 per share and are held directly.

The options vest in equal monthly installments over one year starting on July 11, 2026. They will be fully vested and exercisable on June 11, 2027, or on the date of the 2027 annual meeting of stockholders, whichever occurs first. After this grant, Keating holds 33,350 stock options in total.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider KEATING LAURIE

Role null

Type	Security	Shares	Price	Value
Grant/Award	Stock Option	33,350	$0.00	--

Holdings After Transaction: Stock Option — 33,350 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

Stock options granted: 33,350 options Exercise price: $4.12 per share Total options after grant: 33,350 options +3 more

6 metrics

Stock options granted 33,350 options Grant to director Laurie Keating

Exercise price $4.12 per share Stock option strike price

Total options after grant 33,350 options Holdings following transaction

Option expiration date June 11, 2036 Stock option term

Vesting start July 11, 2026 Monthly vesting commencement

Full vesting date June 11, 2027 Or 2027 annual meeting, whichever first

Key Terms

Stock Option, Class A Common Stock, vests and becomes exercisable, annual meeting of stockholders

4 terms

Stock Option financial

"security_title: "Stock Option""

A stock option is a contract that gives you the right to buy or sell a company's stock at a specific price within a certain time frame. People use them to potentially make money if the stock's price moves favorably or to protect against losses. It's like holding a coupon that can be used to buy or sell stock at a set price later on.

Class A Common Stock financial

"underlying_security_title: "Class A Common Stock""

Class A common stock is a category of a company’s shares that carries a specific set of ownership rights—most commonly defined voting power and claims on dividends—set out in the company’s charter. For investors it matters because the class determines how much influence you have over corporate decisions, the share’s likely dividend and trading behavior, and how it compares in value to other share classes, like choosing a particular seat with different privileges at the company’s decision-making table.

vests and becomes exercisable financial

"The option vests and becomes exercisable in equal monthly installments"

annual meeting of stockholders financial

"or the date of the 2027 annual meeting of stockholders, whichever comes first"

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

KEATING LAURIE

(Last) (First) (Middle)

245 MAIN STREET

SECOND FLOOR

(Street)

CAMBRIDGE MASSACHUSETTS 02142

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Immuneering Corp [ IMRX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/11/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option	$4.12	06/11/2026		A		33,350		(1)	06/11/2036	Class A Common Stock	33,350	$0	33,350	D

Explanation of Responses:

1. The option vests and becomes exercisable in equal monthly installments over a one-year period commencing on July 11, 2026, and will be fully vested and exercisable on June 11, 2027, or the date of the 2027 annual meeting of stockholders, whichever comes first.

Remarks:

	/s/ Michael D. Bookman, Attorney-in-Fact for Laurie B. Keating	06/11/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did Immuneering Corp (IMRX) report for Laurie Keating?

Immuneering reported that director Laurie Keating received a grant of 33,350 stock options. These options relate to Class A common stock and represent a compensation award rather than an open-market purchase or sale of shares.

What is the exercise price of Laurie Keating’s new Immuneering (IMRX) stock options?

The newly granted stock options to director Laurie Keating have an exercise price of $4.12 per share. This means she can buy Immuneering Class A common stock at $4.12 once the options vest and become exercisable.

When do Laurie Keating’s Immuneering (IMRX) stock options vest and become exercisable?

The 33,350 stock options vest in equal monthly installments over one year starting July 11, 2026. They will be fully vested and exercisable on June 11, 2027, or on the date of the 2027 annual meeting of stockholders, whichever happens first.

How many Immuneering (IMRX) stock options does Laurie Keating hold after this Form 4?

After this grant, Laurie Keating holds 33,350 stock options in total. All of these options relate to Immuneering’s Class A common stock and will vest over time according to the disclosed vesting schedule.

Are Laurie Keating’s new Immuneering (IMRX) options a market purchase or a compensation award?

The filing describes the transaction as a grant or award acquisition of 33,350 stock options. This indicates a compensation-related award from Immuneering, not an open-market purchase or sale of existing common shares.